Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OSE 279

Next Previous
Drug Profile

OSE 279

Alternative Names: OSE-279; OSE-279-IL-7

Latest Information Update: 04 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OSE Immunotherapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Lymphoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 26 Feb 2024 Adverse events data and pharmacokinetics data from a phase I/II trial in Solid tumours presented at the ESMO Targeted Anticancer Therapies Congress 2024 (TAT-2024)
  • 26 Feb 2024 Efficacy, pharmacokinetics and adverse event data from phase I/II trial in Solid tumours released by OSE Immunotherapeutics
  • 11 Oct 2023 Efficacy and safety data from phase I/II trial in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer (AACR-NCI-EORTC-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top